{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:12:49Z","timestamp":1793923969008,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13555-025-01550-8","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:52:41Z","timestamp":1760079161000},"page":"3671-3688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7253-2370","authenticated-orcid":false,"given":"Gianluca","family":"Avallone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4173-0282","authenticated-orcid":false,"given":"Andrea","family":"Bombelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-1676","authenticated-orcid":false,"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6196-9788","authenticated-orcid":false,"given":"Caterina","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5469-4517","authenticated-orcid":false,"given":"Ilaria","family":"Trave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5101-159X","authenticated-orcid":false,"given":"Mariateresa","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3263-4353","authenticated-orcid":false,"given":"Elisabetta","family":"Magnaterra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2118-0795","authenticated-orcid":false,"given":"Flavia","family":"Pigliacelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6181-6922","authenticated-orcid":false,"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0464-3356","authenticated-orcid":false,"given":"Serena","family":"Giacalone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8445-7135","authenticated-orcid":false,"given":"Antonio","family":"Portarapillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8661-2822","authenticated-orcid":false,"given":"Cataldo","family":"Patruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6693-766X","authenticated-orcid":false,"given":"Natale","family":"Schettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8933-4626","authenticated-orcid":false,"given":"Laura","family":"Bonzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0121-4812","authenticated-orcid":false,"given":"Elena","family":"Pezzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3142-1831","authenticated-orcid":false,"given":"Camilla","family":"Chello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1987-0623","authenticated-orcid":false,"given":"Niccol\u00f2","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9122-9975","authenticated-orcid":false,"given":"Giovanna","family":"Brunasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6438-5171","authenticated-orcid":false,"given":"Federica","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6774-7080","authenticated-orcid":false,"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7861-9338","authenticated-orcid":false,"given":"Ersilia","family":"Tolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7971-2848","authenticated-orcid":false,"given":"Alan","family":"Azzolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6163-6921","authenticated-orcid":false,"given":"Francesco","family":"Bellinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-4278","authenticated-orcid":false,"given":"Katharina","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0278-2443","authenticated-orcid":false,"given":"Eugenia Veronica","family":"Di Brizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-7451","authenticated-orcid":false,"given":"Carlotta","family":"Gurioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4773-6993","authenticated-orcid":false,"given":"Maria","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5492-3033","authenticated-orcid":false,"given":"Roberta","family":"Giuffrida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7188-7310","authenticated-orcid":false,"given":"Francesca","family":"Barei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7690-7221","authenticated-orcid":false,"given":"Paolo","family":"Calzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0021-911X","authenticated-orcid":false,"given":"Anna Graziella","family":"Burroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7964-3388","authenticated-orcid":false,"given":"Maria","family":"Mariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7249-2556","authenticated-orcid":false,"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3309-8190","authenticated-orcid":false,"given":"Maddalena","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7855-6621","authenticated-orcid":false,"given":"Teresa","family":"Grieco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5237-0463","authenticated-orcid":false,"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1636-8411","authenticated-orcid":false,"given":"Paola","family":"Savoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-1406","authenticated-orcid":false,"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8548-0493","authenticated-orcid":false,"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7919-8141","authenticated-orcid":false,"given":"Luca","family":"Stingeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5485-0172","authenticated-orcid":false,"given":"Anna","family":"Balato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-2557","authenticated-orcid":false,"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8160-4169","authenticated-orcid":false,"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1938-8581","authenticated-orcid":false,"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6734-1366","authenticated-orcid":false,"given":"Silvia Mariel","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"1550_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/bjd\/ljad339","volume":"190","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yang Y, et al. Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study. Br J Dermatol. 2023;190:55\u201361.","journal-title":"Br J Dermatol"},{"key":"1550_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","volume":"405","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405:583\u201396.","journal-title":"Lancet"},{"key":"1550_CR3","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/all.13401","volume":"73","author":"S Barbarot","year":"2018","unstructured":"Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73:1284\u201393.","journal-title":"Allergy"},{"key":"1550_CR4","doi-asserted-by":"publisher","first-page":"1165098","DOI":"10.3389\/fmed.2023.1165098","volume":"10","author":"M Napolitano","year":"2023","unstructured":"Napolitano M, Di Vico F, Ruggiero A, Fabbrocini G, Patruno C. The hidden sentinel of the skin: an overview on the role of interleukin-13 in atopic dermatitis. Front Med. 2023;10:1165098.","journal-title":"Front Med"},{"key":"1550_CR5","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","volume":"130","author":"JK Gittler","year":"2012","unstructured":"Gittler JK, Shemer A, Su\u00e1rez-Fari\u00f1as M, et al. Progressive activation of TH2\/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130:1344\u201354.","journal-title":"J Allergy Clin Immunol"},{"key":"1550_CR6","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder S. Atopic dermatitis. N Engl J Med. 2021;384:1136\u201343.","journal-title":"N Engl J Med"},{"key":"1550_CR7","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/ijms24010837","volume":"24","author":"A Mesjasz","year":"2023","unstructured":"Mesjasz A, Zawadzka M, Cha\u0142ubi\u0144ski M, Trzeciak M. Is atopic dermatitis only a skin disease? IJMS. 2023;24:837.","journal-title":"IJMS"},{"key":"1550_CR8","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s40257-023-00793-5","volume":"24","author":"D Bernardo","year":"2023","unstructured":"Bernardo D, Bieber T, Torres T. Lebrikizumab for the treatment of moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2023;24:753\u201364.","journal-title":"Am J Clin Dermatol"},{"key":"1550_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.18176\/jiaci.0906","volume":"33","author":"J Armario-Hita","year":"2023","unstructured":"Armario-Hita J, Gal\u00e1n-Guti\u00e9rrez M, Dodero-Anillo J, Carrascosa J, Ruiz-Villaverde R. Updated review on treatment of atopic dermatitis. J Investig Allergol Clin. 2023;33:158\u201367.","journal-title":"J Investig Allergol Clin"},{"key":"1550_CR10","doi-asserted-by":"publisher","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European Guideline (EuroGuiDerm) on atopic eczema: living update. Acad Dermatol Venereol. 2025;39(9):1537\u201366. https:\/\/doi.org\/10.1111\/jdv.20639.","DOI":"10.1111\/jdv.20639"},{"key":"1550_CR11","doi-asserted-by":"crossref","unstructured":"Argenziano G, Cusano F, Corazza M, et al. Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA). Ital J Dermatol Venereol. 2024;159:223\u201350. https:\/\/www.minervamedica.it\/index2.php?show=R23Y2024N03A0223. Accessed 2025 May\u00a015.","DOI":"10.23736\/S2784-8671.24.07664-3"},{"key":"1550_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s13555-025-01357-7","volume":"15","author":"JI Silverberg","year":"2025","unstructured":"Silverberg JI, Bieber T, Paller AS, et al. Lebrikizumab vs other systemic monotherapies for moderate-to-severe atopic dermatitis: network meta-analysis of efficacy. Dermatol Ther (Heidelb). 2025;15:615\u201333.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1550_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14712598.2024.2435427","volume":"25","author":"L Stingeni","year":"2025","unstructured":"Stingeni L, Ferrucci S, Amerio P, Foti C, Patruno C, Girolomoni G. Lebrikizumab: a new anti-IL-13 agent for treating moderate-to-severe atopic dermatitis. Expert Opin Biol Ther. 2025;25:15\u201320.","journal-title":"Expert Opin Biol Ther"},{"key":"1550_CR14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/bjd\/ljae394","volume":"192","author":"N Katoh","year":"2025","unstructured":"Katoh N, Tanaka A, Takahashi H, et al. Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase\u00a0III trial in Japan (ADhere-J). Br J Dermatol. 2025;192:597\u2013610.","journal-title":"Br J Dermatol"},{"key":"1550_CR15","doi-asserted-by":"publisher","first-page":"2442720","DOI":"10.1080\/09546634.2024.2442720","volume":"36","author":"A Blauvelt","year":"2025","unstructured":"Blauvelt A, Kircik L, Schlesinger T, et al. Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2025;36:2442720.","journal-title":"J Dermatolog Treat"},{"key":"1550_CR16","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s13555-024-01158-4","volume":"14","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, De Bruin-Weller M, Hong HC, et al. Lebrikizumab provides rapid clinical responses across all Eczema Area and Severity Index body regions and clinical signs in adolescents and adults with moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024;14:1145\u201360.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1550_CR17","doi-asserted-by":"publisher","unstructured":"Hagino T, Uchiyama A, Onda M, et al. 24-Week real-world effectiveness and safety of lebrikizumab for atopic dermatitis in Japan: an analysis stratified by prior systemic therapy. Dermatitis. 2025. https:\/\/doi.org\/10.1089\/derm.2025.0045.","DOI":"10.1089\/derm.2025.0045"},{"key":"1550_CR18","doi-asserted-by":"publisher","unstructured":"Hagino T, Uchiyama A, Onda M, et al. Real-world effectiveness and safety of lebrikizumab for moderate-to-severe atopic dermatitis: a 16-week study in Japan. Dermatitis. 2025. https:\/\/doi.org\/10.1089\/derm.2025.000.","DOI":"10.1089\/derm.2025.000"},{"key":"1550_CR19","doi-asserted-by":"publisher","unstructured":"Hagino T, Uchiyama A, Onda M, et al. Real-world Japanese study of the effectiveness and safety of switching from dupilumab to lebrikizumab in patients with moderate to severe atopic dermatitis. Dermatitis. 2025. https:\/\/doi.org\/10.1089\/derm.2025.0046.","DOI":"10.1089\/derm.2025.0046"},{"key":"1550_CR20","doi-asserted-by":"publisher","unstructured":"Hagino T, Uchiyama A, Kosaka K, et al. Real-world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis. Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.20660.","DOI":"10.1111\/jdv.20660"},{"key":"1550_CR21","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.3390\/jcm12072701","volume":"12","author":"A Chiricozzi","year":"2023","unstructured":"Chiricozzi A, Maurelli M, Calabrese L, Peris K, Girolomoni G. Overview of atopic dermatitis in different ethnic groups. JCM. 2023;12:2701.","journal-title":"JCM"},{"key":"1550_CR22","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20137.","journal-title":"Lancet"},{"key":"1550_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.18176\/jiaci.0138","volume":"27","author":"J Silvestre Salvador","year":"2017","unstructured":"Silvestre Salvador J, Romero-P\u00e9rez D, Encabo-Dur\u00e1n B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol. 2017;27:78\u201388.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"1550_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","volume":"10","author":"JM Hanifin","year":"2001","unstructured":"Hanifin JM, Thurston M, Omoto M, et al. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10:11\u20138.","journal-title":"Exp Dermatol"},{"key":"1550_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"1550_CR26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181:761\u20139.","journal-title":"Br J Dermatol"},{"key":"1550_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12955-021-01877-8","volume":"19","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, DeLozier A, Sun L, et al. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Health Qual Life Outcomes. 2021;19:247.","journal-title":"Health Qual Life Outcomes"},{"key":"1550_CR28","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1007\/s12325-023-02528-8","volume":"40","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP, De Bruin-Weller M, Costanzo A, et al. Baseline body surface area and itch severity define response to baricitinib in patients with moderate-to-severe atopic dermatitis at week\u00a016. Adv Ther. 2023;40:3574\u201387.","journal-title":"Adv Ther"},{"key":"1550_CR29","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jaad.2020.04.104","volume":"83","author":"E Simpson","year":"2020","unstructured":"Simpson E, Bissonnette R, Eichenfield LF, et al. The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83:839\u201346.","journal-title":"J Am Acad Dermatol"},{"key":"1550_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000247298","volume":"186","author":"JF Stalder","year":"1993","unstructured":"Stalder JF, Ta\u00efeb A, Atherton DJ, et al. Severity scoring of atopic dermatitis: the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186:23\u201331.","journal-title":"Dermatology"},{"key":"1550_CR31","doi-asserted-by":"publisher","unstructured":"Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective. Arch Dermatol. 2004;140:1513\u20139. https:\/\/doi.org\/10.1001\/archderm.140.12.1513.","DOI":"10.1001\/archderm.140.12.1513"},{"key":"1550_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/03007995.2019.1699516","volume":"36","author":"DM Pariser","year":"2020","unstructured":"Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis\u00a0Control Tool (ADCT). Curr Med Res Opin. 2020;36:367\u201376.","journal-title":"Curr Med Res Opin"},{"key":"1550_CR33","doi-asserted-by":"publisher","first-page":"ljac140.022","DOI":"10.1093\/bjd\/ljac140.022","volume":"188","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Gooderham M, Katoh N, et al. 327 Optimizing the management of atopic dermatitis with a new minimal disease activity concept and criteria and consensus-based recommendations for systemic therapy. British Journal of Dermatology. 2023;188:ljac140.022.","journal-title":"Br J Dermatol"},{"key":"1550_CR34","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361\u201370.","journal-title":"Acta Psychiatr Scand"},{"key":"1550_CR35","doi-asserted-by":"publisher","unstructured":"Blicharz L, Michalczyk A, Maj M, Czuwara J, Olszewska M, Rudnicka L. Head and neck dermatitis: a variant of atopic dermatitis. Ital J Dermatol Venereol. 2025;160:123\u2013144. https:\/\/doi.org\/10.23736\/S2784-8671.25.08001-6.","DOI":"10.23736\/S2784-8671.25.08001-6"},{"key":"1550_CR36","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Tha\u00e7i D, et al. Two phase\u00a03 trials of Lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388:1080\u201391.","journal-title":"N Engl J Med"},{"key":"1550_CR37","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/bjd\/ljad022","volume":"188","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase\u00a0III trials. Br J Dermatol. 2023;188:740\u20138.","journal-title":"Br J Dermatol"},{"key":"1550_CR38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","volume":"159","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol. 2023;159:182.","journal-title":"JAMA Dermatol"},{"key":"1550_CR39","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","volume":"78","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase\u00a0II trial (TREBLE). J Am Acad Dermatol. 2018;78:863-871.e11.","journal-title":"J Am Acad Dermatol"},{"key":"1550_CR40","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","volume":"156","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase\u00a02b randomized clinical trial. JAMA Dermatol. 2020;156:411.","journal-title":"JAMA Dermatol"},{"key":"1550_CR41","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s13555-024-01226-9","volume":"14","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Wollenberg A, Stein Gold L, et al. Patients with moderate-to-severe atopic dermatitis maintain stable response with no or minimal fluctuations with 1\u00a0year of lebrikizumab treatment. Dermatol Ther (Heidelb). 2024;14:2249\u201360.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1550_CR42","doi-asserted-by":"publisher","first-page":"1429709","DOI":"10.3389\/fphar.2024.1429709","volume":"15","author":"J Lin","year":"2024","unstructured":"Lin J, Luo M, Zhuo Q, Chen N, Zhang H, Han Y. Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1429709.","journal-title":"Front Pharmacol"},{"key":"1550_CR43","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.alit.2024.08.010","volume":"74","author":"M Kido-Nakahara","year":"2025","unstructured":"Kido-Nakahara M, Chiba T, Mizusawa Y, et al. Cytokine profile of the stratum corneum in atopic dermatitis lesions differs between the face and the trunk. Allergol Int. 2025;74:222\u201332.","journal-title":"Allergol Int"},{"key":"1550_CR44","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1038\/s41467-024-46540-0","volume":"15","author":"C Bangert","year":"2024","unstructured":"Bangert C, Alkon N, Chennareddy S, et al. Dupilumab-associated head and neck dermatitis shows a pronounced type\u00a022 immune signature mediated by oligoclonally expanded T\u00a0cells. Nat Commun. 2024;15:2839.","journal-title":"Nat Commun"},{"key":"1550_CR45","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jaad.2022.11.047","volume":"88","author":"LA Beck","year":"2023","unstructured":"Beck LA, Bieber T, Weidinger S, et al. Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial. J Am Acad Dermatol. 2023;88:816\u201323.","journal-title":"J Am Acad Dermatol"},{"key":"1550_CR46","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/cells13161398","volume":"13","author":"J Laska","year":"2024","unstructured":"Laska J, Tota M, \u0141acwik J, S\u0119dek \u0141, Gomu\u0142ka K. IL-22 in atopic dermatitis. Cells. 2024;13:1398.","journal-title":"Cells"},{"key":"1550_CR47","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.jaci.2025.01.013","volume":"155","author":"S Meledathu","year":"2025","unstructured":"Meledathu S, Naidu MP, Brunner PM. Update on atopic dermatitis. J Allergy Clin Immunol. 2025;155:1124\u201332.","journal-title":"J Allergy Clin Immunol"},{"key":"1550_CR48","doi-asserted-by":"publisher","first-page":"e852","DOI":"10.1111\/jdv.19929","volume":"38","author":"N Gori","year":"2024","unstructured":"Gori N, Ippoliti E, Ferrucci SM, et al. Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: a case series. J Eur Acad Dermatol Venereol. 2024;38:e852\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1550_CR49","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/ijd.16926","volume":"63","author":"MA Lasheras-P\u00e9rez","year":"2024","unstructured":"Lasheras-P\u00e9rez MA, Palacios-Diaz RD, Pozuelo-Ruiz M, Torres-Navarro I, Botella-Estrada R, Rodriguez-Serna M. Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects. Int J Dermatol. 2024;63:105\u20137.","journal-title":"Int J Dermatol"},{"key":"1550_CR50","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s13555-023-01058-z","volume":"14","author":"K Rand","year":"2024","unstructured":"Rand K, Ramos-Go\u00f1i JM, Akmaz B, Sol\u00e9-Feu L, Armario-Hita J-C. Matching-adjusted indirect comparison of the long-term efficacy maintenance and adverse event rates of lebrikizumab versus dupilumab in moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024;14:169\u201382.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01550-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01550-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01550-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T10:02:56Z","timestamp":1763200976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01550-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1550"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01550-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Luigi Gargiulo has been a consultant and\/or speaker and has participated to advisory boards for Abbvie, Amgen, Almirall, Novartis, Johnson and Johnson, Eli Lilly, Sanofi, Pierre Fabre, BMS, Leo Pharma, UCB, and Pfizer; Caterina Foti has conflict of interest with AbbVie, Almirall, Amgen, Eli Lilly, Incyte, Leo Pharma, Novartis, and Sanofi; Mariateresa Rossi has served as advisory board member and received honoraria for lectures from Almirall, AbbVie, Sanofi, LEO Pharma, Pfizer, Eli Lilly, L\u2019Or\u00e9al, Galderma; Serena Giacalone has received honoraria from AbbVie, Johnson and Johnson, Almirall, Sanofi, Leo Pharma, and Novartis. Mariateresa Rossi is an Editorial Board member of\n                      Dermatology and Therapy\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Cataldo Patruno acted as investigator, speaker, consultant, and advisory board member for AbbVie, Almirall, Amgen, Eli Lilly, Galderma, Leo Pharma, Novartis, Pfizer, Pierre Fabre, and Sanofi; Natale Schettini acted as a speaker and consultant for Sanofi, AbbVie, Novartis, Almirall, and Leo Pharma; Niccol\u00f2 Gori has served as advisory board member and received honoraria for lectures for Almirall, AbbVie, Sanofi, Leo Pharma, Pfizer, Novartis and Galderma; Giampiero Girolomoni has received personal fees from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Galderma, Eli Lilly, Leo Pharma, Merck Serono, Novartis, Pfizer, Pierre Fabre, Samsung bioepis and Sanofi; Francesca Barei has conflict of interest with Leo Pharma; Katharina Hansel acted as advisor for AbbVie, Almirall, Amgen, BMS, Eli Lilly, Leo Pharma, Novartis, and Sanofi, UCB; Luca Stingeni acted as advisor, speaker and\/or investigator for AbbVie, Almirall, Amgen, BMS, Eli Lilly, Incyte, L\u2019Oreal, Leo Pharma, Novartis, Pfizer, Sanofi, UCB; Angelo Valerio Marzano has conflict of interest with AbbVie, Boehringer Ingelheim, Bristol Myers, Squibb, Incyte, Leopharma, Novartis, Pfizer, Sanofi and UCB; Alessandra Narcisi has served on advisory boards, received honoraria for lectures and research grants from Almirall, Abbvie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi-Genzyme, Amgen and Boehringer Ingelheim; Silvia M. Ferrucci has conflict of interest with Amgen, Sanofi, Novartis, Lilly, Leo Pharma, Abbvie, Novartis, Menarini. All other authors (Gianluca Avallone, Andrea Bombelli, Ilaria Trave, Elisabetta Magnaterra, Flavia Pigliacelli, Piergiorgio Malagoli, Antonio Portarapillo, Laura Bonzano, Elena Pezzolo, Camilla Chello, Giovanna Brunasso, Federica Veronese, Michela Ortoncelli, Ersilia Tolino, Alan Azzolini, Francesco Bellinato, Eugenia Veronica Di Brizzi, Carlotta Gurioli, Maria Esposito, Roberta Giuffrida, Paolo Calzari, Anna Graziella Burroni, Massimo Gola, Maria Mariano, Maria Concetta Fargnoli, Maddalena Napolitano, Teresa Grieco, Ketty Peris, Paola Savoia, Simone Ribero, Anna Balato and Antonio Costanzo) have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study adhered to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) reporting guidelines for cohort studies and the principles outlined in the Declaration of Helsinki. Ethical approval was granted by an institutional review board (Ethics Approval Committee Lombardia 3, protocol number Lebri-AD-2024). All patients provided written informed consent to participate in the study and for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}